Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

The purpose of the study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with PD-1 inhibitors and chemoradiotherapy, in comparison with adjuvant chemotherapy only, in D2/R0 resected pN3 gastric or gastroesophageal junction adenocarcinoma. PD-1+CRT cohort: A total of 216 patients will receive 6 weeks of PD-1 inhibitors and chemotherapy, then receive concurrent chemoradiotherapy, followed by 6 weeks of PD-1 inhibitors and chemotherapy, finally receive maintenance treatment of PD-1 inhibitors until (maximum 1year after radiotherapy). CT cohort: A total of 217 patient

Trial Details

NCT ID
NCT04997837
Phase
PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Gastroesophageal Junction (GEJ) Gastric Cancer
Interventions
  • PD-1 inhibitor
  • Oxaliplatin
  • Capecitabine
  • Tegafur-gimeracil-oteracil potassium
  • 5-FU
  • Radiotherapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
  • Patients with expected survival time more than 6 months
  • Patients after standard D2/R0 resection
  • Postoperative histologically confirmed adenocarcinoma of the stomach or GEJ

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastroesophageal Junction (GEJ) Gastric Cancer Trials on Trialify →